Profound weight loss associated with reboxetine
use in a 44-year-old woman

by
Baldwin DS, Bridgman K, Buis C.
Clinical Neuroscience Division,
School of Medicine,
University of Southampton,
Southhampton, UK.
Br J Clin Pharmacol. 2005 Aug;60(2):218-20.


ABSTRACT

We report a case of significant weight loss experienced by a 44-year-old Caucasian woman treated with reboxetine. She was treated with this drug at 12 mg daily for a total duration of 11 months. During the corresponding period her body mass index (BMI) decreased from a baseline of 21.4 kg m(-2) to a low of 16.8 kg m(-2). Withdrawal of the drug led to a full recovery of her BMI. The strongest evidence linking reboxetine to this woman's weight loss laid in the fact that the re-introduction of the drug subsequently caused a similar negative impact in her BMI.


Efficacy
Selectivity
Reboxetine
Breastmilk
Sexual side-effects
Reboxetine and the elderly
Sexual function on reboxetine
Reboxetine (Edronax) as a discriminative stimulus




Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family